Peeling Back The Layers: Exploring Nurix Therapeutics Through Analyst Insights
Portfolio Pulse from Benzinga Insights
Analysts have provided a range of ratings for Nurix Therapeutics (NASDAQ:NRIX) over the past three months, with a majority being bullish. The average 12-month price target is $28.73, showing a slight increase from the previous target. Key analysts have maintained or raised their ratings, reflecting positive sentiment towards the company's future performance.
June 05, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have shown a predominantly bullish sentiment towards Nurix Therapeutics, with an average 12-month price target of $28.73. Key analysts have maintained or raised their ratings, indicating a positive outlook for the company's stock.
The majority of analysts have given bullish ratings, and the average price target has slightly increased. Key analysts have maintained or raised their ratings, indicating confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100